Quantification of drug-related toxicity associated with the prescribing of inappropriate medicines for patients with limited life expectancy. by Todd,  A. et al.
Durham Research Online
Deposited in DRO:
21 December 2013
Version of attached ﬁle:
Other
Peer-review status of attached ﬁle:
Peer-reviewed
Citation for published item:
Todd, A. and Nazar, H. and Andrew, I. and Baker, L. and Husband, A. (2013) 'Quantiﬁcation of drug-related
toxicity associated with the prescribing of inappropriate medicines for patients with limited life expectancy.',
International journal of pharmacy practice., 21 (S2). pp. 90-91.
Further information on publisher's website:
http://dx.doi.org/10.1111/ijpp.12064
Publisher's copyright statement:
This is the peer reviewed version of the following article: (2013), Research Posters. International Journal of Pharmacy
Practice, 21 (S2): 30137, which has been published in ﬁnal form at http://dx.doi.org/10.1111/ijpp.12064. This article
may be used for non-commercial purposes in accordance With Wiley Terms and Conditions for self-archiving.
Additional information:
Issue subtitle: Abstracts of the Royal Pharmaceutical Society (RPS) Annual Conference 2013, 8-9 September 2013,
Birmingham, UK.
Use policy
The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-proﬁt purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom
Tel : +44 (0)191 334 3042 | Fax : +44 (0)191 334 2971
http://dro.dur.ac.uk
 
Title: 
Quantification of drug-related toxicity associated with the prescribing of inappropriate medicines for patients with limited 
life expectancy. 
 
Abstract:  
Focal points 
1. Polypharmacy is common amongst patients with limited life expectancy; 
2. Prescribing of inappropriate medicines for patients with limited life expectancy can lead to multiple drug interactions 
of varying severity; 
3. Patients with limited life expectancy should have their medicines reviewed in line with the original therapeutic goals. 
  
Background  
For patients with limited life expectancy – typically surviving for less than one year from diagnosis – polypharmacy is 
common as medication is prescribed to manage both life limiting illness and to treat or prevent other long-term 
conditions. Consequently, there is an increased risk of developing drug-related toxicity resulting from drug-drug or drug-
disease interactions.  The aim of this work was to assess the prevalence of inappropriate medication and identify any 
potential theoretical drug-drug interactions in patients attending a specialist palliative care unit. 
 
Methods 
This was a prospective study that examined medication and medical histories for patients attending a specialist palliative 
care day care centre from November 2012 until March 2013. Medication was assessed for appropriateness using a 
conceptual framework, which considers remaining life expectancy of the patient, time until benefit of the treatment, goals 
of care and treatment targets.
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 Consensus was reached via Delphi methodology using a range of clinical pharmacists and 
consultants in palliative medicine; to reach consensus agreement was required from all panel members.  Drug interactions 
were identified and assessed according to significance using the drug interaction recognition software, Proscript.  Drug 
interactions identified as significant were further sub-classified as moderate or severe based upon the potential to cause 
harm or hospitalisation, if they were reversible or irreversible and, if any treatment would be required to manage the 
outcome.   
 
Results  
A total of 132 patients were assessed during the study period, 108 (82%) had cancer, 8 (6%) congestive heart failure, 11 
(8%) severe chronic obstructive pulmonary disease and 5 (4%) Parkinson’s disease.  In total, the number of medications 
taken was 1532 (mean per patient, 12; range 1 to 21).  Of the 1532 medicines assessed, 238 (16%) were considered to be 
inappropriate given the patients limited life expectancy.  Out of the 132 patients assessed, 92 (70%) were taking at least 
one inappropriate medication. The most common therapeutic group considered inappropriate were the statins, which were 
prescribed in 35 patients (27%). The drug interaction recognition software identified a total of 267 potential drug 
interactions: 155 were considered non-significant, while 112 were classified as significant.  Among those identified as 
significant, 92 were considered moderate while 20 were considered severe.  In our study, discontinuing inappropriate 
medicine would prevent 57 non-significant, 23 moderate and 8 severe potential drug interactions. The most frequent 
major potential drug interaction that could be prevented by discontinuing inappropriate medication was between 
simvastatin (> 20 mg daily) and amlodipine, a well-defined drug interaction, which increases the risk of myopathy; this 
was identified in 4 patients.   
 
Discussion 
Our results show that the majority of people accessing the day care centre in a specialist palliative care unit are being 
prescribed many inappropriate medications in view of their life limiting illness. These inappropriate medications 
contribute to potential drug interactions and thereby increase the risk of patients developing drug-related toxicty.  Our 
findings are consistent with the literature and build upon our previous work that showed patients with advanced lung 
cancer take many inappropriate medications, some of which can potentially interact with chemotherapy and contribute to 
negative outcomes for patients.
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  In conclusion, these findings demonstrate there is potential for pharmacists to become 
involved in medication review for patients with limited life expectancy in order to faciliate discontinuation of 
inappropriate medication in the context of the origninal therapeutic goals.  
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